Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib.

American heart journal - 1 Apr 2020

Tardif Jean-Claude, Dubé Marie-Pierre, Pfeffer Marc A, Waters David D, Koenig Wolfgang, Maggioni Aldo P, McMurray John J V, Mooser Vincent, White Harvey D, Heinonen Therese, Black Donald M, Guertin Marie-Claude

Abstract excerpt

The objectives of precision medicine are to better match patient characteristics with the therapeutic intervention to optimize the chances of beneficial actions while reducing the exposure to unneeded adverse drug experiences. In a retrospective genome-wide association study of the overall neutral placebo-controlled dal-Outcomes trial, the effect of the cholesteryl ester transfer protein (CETP) modulator...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenylyl Cyclases
Share to Amides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anticholesteremic Agents

Share to Atherosclerosis

Share to Double-Blind Method

Share to Esters

Share to Global Health

Share to Sulfhydryl Compounds

Source

Identifiers

PMID: 32087417
DOI: 10.1016/j.ahj.2020.01.007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib.PMID 32087417Read ↗

CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib.Semantic proximity Read ↗

Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine.Semantic proximity Read ↗

Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes.Semantic proximity Read ↗

ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.Semantic proximity Read ↗

Advancing Beyond Failed High-density Lipoprotein Clinical Trials to Pharmacogenetic Studies of ADCY9 and Cholesterol Ester Transfer Protein Inhibition.Semantic proximity Read ↗

CETP inhibition and <i>ADCY9</i> genotype: evidence of a qualitative pharmacogenetic interaction in cardiovascular disease?Semantic proximity Read ↗

A sex-specific evolutionary interaction between ADCY9 and CETP.Semantic proximity Read ↗

A sex-specific evolutionary interaction between <i>ADCY9</i> and <i>CETP</i>Semantic proximity Read ↗

Phosphodiesterase 5 and its inhibitors with ischaemic heart disease: a Mendelian randomization analysis and a real-world study.Semantic proximity Read ↗

Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular DiseaseSemantic proximity Read ↗

Cholesteryl Ester Transfer Protein as a Drug Target for Cardiovascular DiseaseSemantic proximity Read ↗

Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.